AETERNA INVENTIO advances precision and translational medicine by discovering, validating, and applying biomarkers that reflect the complexity of human biology. Health and disease arise from the interconnected influences of molecular, genetic, polygenic, microbial, environmental, and phenotypic factors, yet traditional approaches often examine these dimensions separately. Our mission is to decode these complex systems, transforming diverse biological data into actionable insights that guide clinical decisions, preventive strategies, and public health initiatives.

We integrate AI-driven multi-omics analysis, whole genome sequencing (WGS), polygenic modeling, interactomics, microbiome profiling, and phenotypic biomarker discovery to create a mechanism-informed, polygenicity-aware understanding of human health:

  • Genomics & WGS: identification of DNA variants, structural changes, and genome-wide patterns shaping disease risk, regenerative potential, and intervention response.
  • Polygenic Modeling: calculation of Polygenic Risk Scores (PRS) and Polygenic Risk Factors (PRF) to quantify cumulative genetic risk and stratify individuals for susceptibility and regenerative potential.
  • Transcriptomics: gene expression profiling to reveal dynamic cellular activity and regulatory pathways.
  • Proteomics: characterization of proteins as functional mediators connecting genotype and phenotype.
  • Metabolomics: mapping metabolic networks and small molecules to monitor physiological and pathological processes.
  • Epigenomics: assessment of chemical modifications that regulate gene expression in response to environment, lifestyle, or interventions.
  • Interactomics: reconstruction of molecular and protein–protein interaction networks to understand system-level regulation and disease mechanisms.
  • Microbiome Analysis: evaluation of microbial communities to reveal their influence on metabolism, immunity, regenerative response, cognition, and disease susceptibility.
  • Phenotypic Biomarkers: visual, histopathological, and functional readouts—including high-resolution imaging and biopsies—linking molecular and polygenic data to tissue- and organ-level outcomes.

This integrated, multi-scale, and polygenicity-informed approach provides a holistic view of human biology, enabling stratified risk assessment, early intervention, and personalized preventive strategies that bridge discovery with clinical application.

Translational Impact and Pilot Studies

AETERNA INVENTIO transforms fundamental science into practical, ethically grounded applications through pilot studies and proof-of-concept projects in collaboration with hospitals and clinical partners:

  1. Predictive and Preventive Medicine: Polygenic Risk Scores combined with multi-omics and microbiome data allow precise assessment of individual susceptibility to common and rare diseases.
  2. Regenerative Medicine: PRF- and PRP-mediated tissue regeneration guided by molecular, polygenic, and visual biomarkers, evaluated through clinical pilot projects.
  3. Cognition Enhancement and Nootropics: mechanism-informed research into cognitive function, neuroprotection, and wellness interventions, assessed through polygenic, molecular, microbiome, and phenotypic biomarkers.
  4. Functional Cosmetics and Nutraceuticals: evidence-based development and evaluation of interventions targeting skin, metabolic, and cognitive health, supported by pilot studies.
  5. Microbiome-Informed Strategies: leveraging microbial signatures to optimize regenerative, metabolic, and cognitive outcomes in clinical and translational contexts.
  6. Public Health Applications: data-driven approaches for early detection, risk stratification, targeted interventions, and optimized healthcare resource allocation, evaluated in pilot programs with hospitals and institutional partners.

Mission

To translate polygenic, molecular, microbial, and phenotypic information into validated, actionable knowledge that supports clinical decisions, preventive care, regenerative therapies, cognition-support interventions, and improved outcomes for individuals and populations.

Vision

We envision a healthcare landscape guided by system-level understanding, where integrated multi-omics, WGS, polygenicity, interactomics, microbiome, and phenotypic data, supported by pilot study evidence, inform precision, prevention, and personalization. AETERNA INVENTIO bridges research, clinical practice, and societal impact, enabling smarter, equitable, and evidence-driven healthcare.

Societal Impact

Our work delivers dual benefits:

  • For clinicians and patients: mechanism- and polygenicity-informed insights reduce uncertainty, support early intervention, regenerative therapies, cognition-support, and preventive strategies.
  • For healthcare systems and society: optimized resource allocation, targeted interventions, and proactive care ensure healthcare reaches those who need it most.

From Data to Actionable Knowledge

By integrating whole genome sequencing, polygenic modeling, multi-omics, interactomics, microbiome profiling, phenotypic evaluation, and pilot study evidence, combined with AI-assisted interpretation, AETERNA INVENTIO transforms complex biological and environmental data into clinically meaningful and socially relevant knowledge. This framework underpins personalized healthcare, stratified prevention, regenerative medicine, cognition-support interventions, and mechanism-informed functional products, delivering measurable impact under the highest scientific, ethical, and regulatory standards.